Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2021

View Archived Issues

CARB-X grant supports development of SNIPR-001 to prevent E. coli infections in cancer patients

First-in-human PET imaging study and radiation dosimetry of thiamine derivative [11C]TTFD

Eph/ephrin inhibitor UniPR-1331 counters inflammation in Crohn's disease model

TUBB4B inhibition could treat nonalcoholic fatty liver disease-associated hepatocellular carcinoma

Phase I/II study of RVU-120 in solid tumors approved in Poland

Gene therapy can address infantile Parkinson's

Guangzhou Henovcom Bioscience patents ENPP2 inhibitors

Northwest Agriculture & Forestry University divulges new DprE1 inhibitors

Chinese investigators disclose new componds for schizophrenia

Nanjing Sanhome Pharmaceutical synthesizes PTPN11 inhibitors

Affibody describes new compounds for HMGB1-related disorders

Ziltivekimab reduces biomarkers of inflammation and thrombosis in phase II RESCUE study

Phase I trial investigates MT-6402 in PD-L1-expressing advanced solid cancer

NIDA studies TRV-734 in phase II for opioid use disorder

BPRCX-807 demonstrates promising activity in models of HCC

Enrollment opens in phase IIb study of ARO-APOC3 in severe hypertriglyceridemia

Phase I trial explores use of BIVV-001 in adults with type 2N and 3 von Willebrand disease

RNF6 and SF3B2 are novel therapeutic targets in colorectal cancer

Disulfiram/copper gluconate studied in phase I for treatment-refractory multiple myeloma

Liminal stops plans to advance fezagepras into trials for IPF and hypertriglyceridemia

SCOHIA advances somatostatin SST5 receptor antagonist SCO-240 into phase I study

Prefusion F-based nanovaccine confers durable protection against RSV infection in mice

Extracellular nicotinamide phosphoribosyltransferase suggested as a viable ARDS therapeutic target

SRSF2 is an oncogenic factor in PDAC and PC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...